Botanix Pharmaceuticals Limited
BXPHF
$0.099
-$0.001-1.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 170.50% | 204.33% | 374.95% | -1.55% | -46.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 170.50% | 204.33% | 374.95% | -1.55% | -46.24% |
| Cost of Revenue | 1.00% | 43.49% | 139.32% | 2.45% | -37.60% |
| Gross Profit | 220.98% | 102.27% | -52.89% | -7.79% | 20.96% |
| SG&A Expenses | 557.26% | 481.34% | 368.27% | 258.01% | 102.78% |
| Depreciation & Amortization | 2,971.91% | 1,833.33% | 1,035.32% | 485.89% | -36.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 441.60% | 385.99% | 303.94% | 150.58% | 21.54% |
| Operating Income | -481.75% | -404.91% | -300.87% | -183.61% | -49.46% |
| Income Before Tax | -510.81% | -416.66% | -290.08% | -176.78% | -47.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -510.81% | -416.66% | -290.08% | -176.78% | -47.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -510.81% | -416.66% | -290.08% | -176.78% | -47.71% |
| EBIT | -481.75% | -404.91% | -300.87% | -183.61% | -49.46% |
| EBITDA | -468.77% | -392.63% | -289.88% | -177.61% | -49.02% |
| EPS Basic | -400.00% | -312.96% | -208.33% | -105.88% | -11.11% |
| Normalized Basic EPS | -394.74% | -311.76% | -200.00% | -106.25% | -11.76% |
| EPS Diluted | -400.00% | -312.96% | -208.33% | -105.88% | -11.11% |
| Normalized Diluted EPS | -394.74% | -311.76% | -200.00% | -106.25% | -11.76% |
| Average Basic Shares Outstanding | 22.87% | 23.45% | 24.08% | 26.85% | 30.12% |
| Average Diluted Shares Outstanding | 22.87% | 23.45% | 24.08% | 26.85% | 30.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |